BioNTech (BNTX) vs Mirum Pharmaceuticals (MIRM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Mirum Pharmaceuticals (MIRM) has outperformed BioNTech (BNTX) over the past year, gaining 16.5% versus a loss of 7.2%. Over five years, MIRM leads with a +402.4% price change compared with -60.9% for BNTX. BioNTech is the larger company by market cap ($24.36 billion vs $5.58 billion), about 4.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BNTX | MIRM |
|---|---|---|
| Share price | $96.96 | $86.01 |
| Market cap | $24.36B | $5.58B |
| 1-day change | +5.32% | +5.73% |
| YTD return | +1.85% | +8.89% |
| 1-year return | -7.20% | +16.51% |
| 5-year return | -60.85% | +402.39% |
| EPS (TTM) | $-7.83 | $-14.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $521.31M |
| Revenue growth (YoY) | — | +54.74% |
| Net income (latest FY) | — | $-23.36M |
| Operating margin | — | -4.25% |
| Net margin | — | -4.48% |
| 52-week high | $124.00 | $130.00 |
| 52-week low | $79.52 | $63.23 |
| Distance from 52-week high | -21.81% | -33.84% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +19.85% | +69.50% |
| Average volume | 1.17M | 695.76K |
| Shares outstanding | 251.20M | 64.93M |
| Employees | 7,807 | 433 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BioNTech is about 4.4 times larger than Mirum Pharmaceuticals by market value ($24.36B vs $5.58B).
- MIRM has outperformed BNTX by 23.7 percentage points over the past year.
About BioNTech
BNTX stock →BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 7,807 employees
About Mirum Pharmaceuticals
MIRM stock →Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 433 employees
BNTX vs MIRM FAQ
Which is bigger, BioNTech or Mirum Pharmaceuticals?
BioNTech (BNTX) is larger, with a market capitalization of $24.36B compared with $5.58B for Mirum Pharmaceuticals (MIRM).
Which stock has performed better over the past year, BNTX or MIRM?
MIRM returned +16.51% over the past 12 months, compared with -7.20% for BNTX (price return, excluding dividends). Past performance does not predict future results.
Are BioNTech and Mirum Pharmaceuticals in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for BioNTech and Biotechnology: Pharmaceutical Preparations for Mirum Pharmaceuticals.